73 results
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information … delivery.
The underwriters and other persons acting as agents will not have any responsibility in respect of the validity or performance of delayed
S-3ASR
EX-4.3
sc725rf d4
2 Jan 24
Automatic shelf registration
4:06pm
CORRESP
51bc3vxqfcid3cw9
27 Oct 23
Correspondence with SEC
12:00am
8-K
EX-1.1
zxhyte
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.2
ndvfuvx61019d 78l0
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
nntfrdgnwyeb88hj45v
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
4g0hh1
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-1.1
3jucibz7rtpizpv01
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
pmi a9af4yob4
30 Mar 22
Prospectus supplement for primary offering
5:21pm